Skip to main content

Table 3 Calculation results of base cases. Standard deviations are shown in parentheses

From: The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling

 

MSM-dg

MSM-kf

Immunosuppressant therapy

Control

Immunosuppressant therapy

Control

Life years (years)

76.35 (± 12.44)

73.89 (± 12.14)

78.80 (± 12.62)

75.80 (± 12.82)

Utility (years)

20.34 (± 4.08)

19.43 (± 4.06)

21.12 (± 4.08)

20.00 (± 4.33)

Cost (1000 USD)

199.98 (± 298.13)

286.85 (± 350.27)

122.99 (± 265.59)

213.42 (± 365.60)

V0 (1000 USD)

86.87

90.43

V1 (1000 USD)

132.29

146.25

  1. MSM-dg Disease grade-based microsimulation, MSM-kf Kidney function-based microsimulation, V0 boundary below which the intervention is dominant; V1 boundary below which the intervention is cost-effective. V0 and V1 are defined in the main text